 Tiziana Life Sciences PLC NASDAQTLSA, LON:TILS said it has signed a deal with contract research group FHI Clinical to carry out a phase II, proof-of-concept study on its nasally-administered antibody treatment for Covid. Foralumab will be given to hospitalised patients with severe coronavirus as part of the Brazil trial that will build on earlier work in mild-to-moderate cases which confirmed the safety and tolerability of the drug as well as its potential efficacy. 